NeuroMetrix, Inc. announced that it plans to issue its 2023 fourth quarter and year end business and financial highlights before the opening of the market on February 22, 2024.
WOBURN, Mass., Feb. 15, 2024 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) announced today that it plans to issue its 2023 fourth quarter and year end business and financial highlights before the opening of the market on February 22, 2024. The Company will host a conference call at 8:00 a.m., Eastern Time on February 22, 2024.
For participants who wish to access the Q4 and year end 2023 Conference Call live via telephone and be able to ask questions, please register in advance here. Upon registering, a dial-in and unique PIN will be provided on screen and via email to join the call. An audio-only webcast of the call, along with the earnings press release and accompanying condensed financial statements, may be accessed in the Investors section of the Company’s website at www.NeuroMetrix.com. Following the conference call, a replay of the call will be available for one year on the Company’s Investors section of the website.
About NeuroMetrix
NeuroMetrix is a commercial stage healthcare company that develops and commercializes neurotechnology devices to address unmet needs in the chronic pain and diabetes markets. The Company’s products are wearable or hand-held medical devices enabled by proprietary consumables and software solutions that include mobile apps, enterprise software and cloud-based systems. The Company has two commercial brands. Quell® is a wearable neuromodulation platform. DPNCheck® is a point-of-care screening test for peripheral neuropathy. For more information, visit www.NeuroMetrix.com.
NeuroMetrix, Inc.
Thomas T. Higgins
SVP and Chief Financial Officer
neurometrix.ir@neurometrix.com
Source: NeuroMetrix, Inc.
